For years, researchers have attempted to stabilize acetylsalicylic acid (ASA) in liquid form without success. Auxesis Pharma is the first to solve this complex chemical challenge. The result is a pharmaceutical breakthrough with the potential to redefine pain treatment globally. The company is now prepared to scale operations and enter international markets.
We have developed a stable liquid formulation of acetylsalicylic acid, representing a new category of topical analgesic. Applied directly to the skin, it acts locally and rapidly, and holds potential for use in both human and veterinary medicine.
Why Is This Important?
Acetylsalicylic acid has been one of the most widely used pharmaceutical substances globally for over a century. Despite its extensive use, it has only existed in tablet form due to degradation and instability in liquid formulations. A stable liquid preparation has long been regarded as chemically unachievable.
Our solution enables a new therapeutic category: localized pain and skin irritation, where existing alternatives are often systemic, slower acting, or limited in efficacy.
Effect: Rapid and Localized Analgesic Action
The key differentiator of our innovation is its localized mechanism of action. It works directly at the site of pain, providing faster relief with reduced systemic exposure compared to oral analgesics.
Market Opportunity: Large and Expanding
The demand for effective topical solutions is substantial across both human and veterinary healthcare. Skin pain, irritation, inflammation and chronic dermatological conditions affect millions of individuals worldwide.
Our Strategy: From Breakthrough to Global Launch
Auxesis Pharma has established an organization of approximately 14–15 professionals and two subsidiaries. Manufacturing scale-up is being prepared in Sweden while regulatory and clinical preparations continue. The objective is to launch in the Nordic region before expanding internationally.
Investment Opportunity
We are seeking long-term investors to support the scale-up of a patented pharmaceutical innovation with global potential. Capital will be allocated toward regulatory pathways, clinical milestones, production scale-up and commercialization.